JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(3):158-163 | DOI: 10.36290/csf.2025.028

Current trends in the teatment of multiple sclerosis

Jana Libertínová
Neurologická klinika, 2. LF UK Praha

Multiple sclerosis is a chronic disease of the central nervous system, in the pathogenesis of which both autoimmune inflammation and neurodegeneration play a role. It is a serious disease diagnosed most often in young adulthood and, without treatment, is the most common cause of non-traumatic disability at this age. Therapy, which is currently available immediately after diagnosis, leads to a significant improvement in the prognosis and quality of life of patients.

Keywords: multiple sclerosis, pathogenesis, highly effective treatment, disease-modifying drugs.

Accepted: September 15, 2025; Published: October 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Libertínová J. Current trends in the teatment of multiple sclerosis. Čes. slov. farm. 2025;74(3):158-163. doi: 10.36290/csf.2025.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 40 CZK

    References

    1. Franklin RJM, Ffrench Constant C, Edgar JM, et al. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012;8:624-634. Go to original source...
    2. Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022 Sep 14;145(9):3147-3161. Go to original source...
    3. Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. WIREs Mech Dis. 2023 Jan;15(1):e1583. Go to original source...
    4. Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710-721. Go to original source...
    5. Luchetti S, Fransen NL, Van Eden CG, et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 2018;135:511-528. Go to original source...
    6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr;46(4):907-11. Go to original source...
    7. Horáková D. Roztroušená skleróza a úloha praktického lékaře. Med. praxi 2008; 10: 378-382.
    8. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286. Go to original source...
    9. Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Mult Scler Relat Disord. 2015;4(4):329-333. Go to original source...
    10. Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering MS, the real MS. Ther Adv Neurol Disord. 2022;15:17562864211066751. Go to original source...
    11. Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high efficacy disease modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269(3):1670-1677. Go to original source...
    12. Brown JW, Coles A, Horáková D, et al. Association of initial disease modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175-187. Go to original source...
    13. Muraro PA, Mariottini A, Greco R, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT. Nat Rev Neurol. 2025;21:140-158. Go to original source...
    14. Šťastná D, Horáková D. Ovlivnění dlouhodobé progrese roztroušené sklerózy - svítá na lepší časy?. Neurol praxi. 2021;22(1):40-44. Go to original source...
    15. Šťastná D, Menkyová I, Horáková D. Progresivní RS ve světle nejnovějších poznatků. Cesk Slov Neurol N. 2023;86(1):10-17.
    16. Kramer J, Bar Or A, Turner TJ, et al. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19:289-304. Go to original source...
    17. Cree BAC, Oksenberg JR, Hauser SL. Multiple sclerosis: two decades of progress. Lancet Neurol. 2022;21(3):211-214. Go to original source...
    18. Okuda DT, Kantarci O, Lebrun Frénay CH, et al. Dimethyl fumarate delays multiple scle­rosis in radiologically isolated syndrome. Ann Neurol. 2023;93(3):604-614. Go to original source...
    19. Lebrun-Frénay C, Siva A, Sormani MP, et al. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial. JAMA Neurol. 2023 Oct 1;80(10):1080-1088. Go to original source...
    20. Horáková D. Jaká data nabízí celostátní registr pacientů s roztroušenou sklerózou ReMuS?. Neurol praxi. 2020;21(5):410-413. Go to original source...
    21. McDonald S, Clements JN. Dalfampridine: a new agent for symptomatic management of multiple sclerosis. Am J Health Syst Pharm. 2011;68(24):2335-2340. Go to original source...
    22. Novotná K, Lízrová Preiningerová J. Možnosti zlepšení chůze u pacientů s roztroušenou sklerózou s RS. Neurol praxi. 2022;23(3):239-244. Go to original source...
    23. Uher T, Havrdová EK, Vodehnalová K, et al. Pregnancy induced brain magnetic resonance imaging changes in women with multiple sclerosis. Eur J Neurol. 2022;29(5):1446-1456. Go to original source...
    24. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-1390.e2. Go to original source...
    25. Šťastná D, Menkyová I, Horáková D. Vysoce účinná terapie již od první ataky - důležitý posun v léčbě roztroušené sklerózy?. Neurol praxi. 2023;24(1):40-44. Go to original source...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.